Innate inflammatory markers for predicting survival in retroperitoneal sarcoma

Yael Netanyahu, Fabian Gerstenhaber, Sivan Shamai, Osnat Sher, Ofer Merimsky, Joseph M. Klausner, Guy Lahat, Eran Nizri*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Introduction: Existing prognostic tools for retroperitoneal sarcomas (RPS) utilize parameters that can be accurately determined only postoperatively. This study evaluated the application of the neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) levels for predicting prognosis in primary RPS. Materials and Methods: We retrospectively analyzed our database of patients with primary RPS operated between 2008 and 2018. The NLR was calculated from preoperative blood tests and its association with outcomes was determined. Results: The NLR values of 78 suitable patients were analyzed. Patients were classified in the NLR-high group if the NLR was ≥2.1. High-grade tumors were more common in the NLR-high group (71.6% vs 48%, P =.02). NLR-high patients had impaired overall survival (OS) and progression-free survival (PFS) compared to NLR-low patients (median OS not reached vs 74 months 95% confidence interval [CI]: 21.6-126.4, P =.03; median PFS not reached vs 48 months 95% CI: 6.5-98.6, P =.06, respectively). Multivariate analysis showed statistical significance only for PFS but not for OS (hazard ratio [HR] = 4.1, P =.03; HR = 2.3, P =.3). Patients with low CRP levels had improved OS and PFS. Conclusions: The NLR may serve as a preoperative, easily derived marker for prognosis in RPS. Serum biomarkers may prove useful in these large and spatially heterogeneous tumors.

Original languageEnglish
Pages (from-to)1655-1661
Number of pages7
JournalJournal of Surgical Oncology
Issue number8
StatePublished - 15 Dec 2020


  • biomarkers for prognosis
  • innate inflammatory response
  • neutrophil-to-lymphocyte ratio
  • retroperitoneal sarcoma


Dive into the research topics of 'Innate inflammatory markers for predicting survival in retroperitoneal sarcoma'. Together they form a unique fingerprint.

Cite this